Company will exploit its proprietary platform technology to develop a new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets in oncology. 

The Peptin technology harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein. 

The technology allows for the rational design of novel biotherapeutics and differentiates itself from any other therapeutic modality through its unique mode of action, its designability and intracellular target space out of reach for other therapeutics.

https://aelintx.com/